Medpace (NASDAQ:MEDP) President Jesse Geiger Sells 31,707 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) President Jesse Geiger sold 31,707 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president directly owned 15,000 shares in the company, valued at $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Medpace Trading Up 1.3%

Medpace stock traded up $6.12 during trading hours on Thursday, reaching $460.92. 285,609 shares of the company were exchanged, compared to its average volume of 345,623. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $628.92. The stock has a 50-day moving average of $514.72 and a 200 day moving average of $538.54. The firm has a market cap of $13.08 billion, a price-to-earnings ratio of 30.13, a PEG ratio of 2.18 and a beta of 1.44.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The company had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The company’s quarterly revenue was up 32.0% compared to the same quarter last year. During the same quarter last year, the firm posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on MEDP. Mizuho set a $582.00 price target on shares of Medpace in a report on Wednesday, February 11th. Truist Financial cut their price objective on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research report on Wednesday, February 11th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Medpace in a report on Wednesday, February 11th. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a research report on Friday, February 13th. Finally, Royal Bank Of Canada initiated coverage on Medpace in a report on Tuesday, March 3rd. They set an “outperform” rating and a $522.00 price target for the company. Five analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $486.67.

Institutional Investors Weigh In On Medpace

Several hedge funds have recently made changes to their positions in the stock. Fifth Third Wealth Advisors LLC lifted its position in shares of Medpace by 2.6% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock worth $379,000 after buying an additional 19 shares during the period. BOKF NA grew its position in Medpace by 0.8% in the third quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after acquiring an additional 20 shares during the period. Valeo Financial Advisors LLC raised its stake in Medpace by 5.0% during the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after acquiring an additional 21 shares in the last quarter. HighPoint Advisor Group LLC raised its stake in Medpace by 2.8% during the third quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock worth $416,000 after acquiring an additional 22 shares in the last quarter. Finally, UMB Bank n.a. lifted its holdings in shares of Medpace by 5.6% during the fourth quarter. UMB Bank n.a. now owns 450 shares of the company’s stock valued at $253,000 after acquiring an additional 24 shares during the period. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.